Americord Releases Cord Blood Stem Cells to Treat Child with Sickle Cell Disease
Americord Registry®, a leader in the cord blood industry, has recently released umbilical cord blood to a family for the treatment of a child with sickle cell disease.
Sickle cell diseases affects more than 20 million people globally, according to the National Heart, Lung, and Blood Institute. The FDA has approved the treatment using umbilical cord blood-derived hematopoietic stem cells (UCB-HSCs) to help treat patients with sickle cell disease.
Americord’s release allowed doctors to treat a child with sickle cell disease with cord blood stem cells from a sibling who did not have the condition.
“Our biggest hope is that families who bank their child’s stem cells and perinatal tissues with Americord never need to use them,” said Martin Smithmyer, Founder and CEO. “But if they do, we’re always prepared to release them to the family’s medical team for treatment quickly and efficiently.”
Americord has released stem cells to Duke University, Riley Hospital, Nicklaus Children’s Hospital, and the Dana-Farber Cancer Institute for medical treatments and clinical trials. These stem cells and perinatal tissues have been used to treat a range of conditions, including autism spectrum disorders (ASDs), sickle cell disease, cerebral palsy, and hydrocephalus.
Since 2008, Americord has aimed to improve and extend human life, leading the field with cutting edge and proprietary cell and tissue based therapeutics and services, including the cryopreservation of stem cells for newborns and their families for future therapeutic use.
The views, statements, and pricing expressed are deemed reliable as of the published date. Articles may not reflect current pricing, offerings, or recent innovations.